GB202203627D0 - Agents for treating complement-related disorders - Google Patents
Agents for treating complement-related disordersInfo
- Publication number
- GB202203627D0 GB202203627D0 GBGB2203627.1A GB202203627A GB202203627D0 GB 202203627 D0 GB202203627 D0 GB 202203627D0 GB 202203627 A GB202203627 A GB 202203627A GB 202203627 D0 GB202203627 D0 GB 202203627D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- agents
- related disorders
- treating complement
- complement
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2203627.1A GB202203627D0 (en) | 2022-03-16 | 2022-03-16 | Agents for treating complement-related disorders |
| PCT/EP2023/056794 WO2023175099A1 (en) | 2022-03-16 | 2023-03-16 | Agents for treating complement-related disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2203627.1A GB202203627D0 (en) | 2022-03-16 | 2022-03-16 | Agents for treating complement-related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202203627D0 true GB202203627D0 (en) | 2022-04-27 |
Family
ID=81255000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2203627.1A Ceased GB202203627D0 (en) | 2022-03-16 | 2022-03-16 | Agents for treating complement-related disorders |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB202203627D0 (en) |
| WO (1) | WO2023175099A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU103244B1 (en) | 2024-02-14 | 2025-08-14 | Univ Hamburg Eppendorf Uke | Deletion of the mouse homolog of human FHR1 (FHRE) protects ApoE-/- mice from atherosclerosis |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100909681B1 (en) | 2000-12-01 | 2009-07-29 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | Small RNA molecules that mediate JR interference |
| WO2008048675A2 (en) | 2006-10-20 | 2008-04-24 | Celldex Therapeutics, Inc. | Treatment for age-related macular degeneration and other diseases of the eye |
| CA2704447A1 (en) | 2007-11-01 | 2009-05-07 | University Of Iowa Research Foundation | Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715 |
| WO2013082563A1 (en) | 2011-12-01 | 2013-06-06 | Protevobio, Inc. | Protein inhibitors to complement and vegf pathways and methods of use thereof |
| US20150157675A1 (en) | 2012-04-02 | 2015-06-11 | Sung Kyun Biotech Co., Ltd. | Composition comprising eupatorium spp. extract as active ingredient for preventing and treating obesity and metabolic bone disease |
| BR112014030677A2 (en) | 2012-06-08 | 2022-07-19 | Shire Human Genetic Therapies | pulmonary distribution of mrna to non-pulmonary target cells |
| JP7068203B2 (en) | 2016-06-28 | 2022-05-16 | ウニベルジテート ウルム | Complement inhibitors and their use |
| GB201709222D0 (en) * | 2017-06-09 | 2017-07-26 | Univ Manchester | C3b Inactivating Polypeptide |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| EP3791180A1 (en) | 2018-05-10 | 2021-03-17 | The University Of Manchester | Methods for assessing macular degeneration |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| GB202006789D0 (en) * | 2020-05-07 | 2020-06-24 | Univ Manchester | Detection of complement proteins |
| WO2022058447A1 (en) | 2020-09-16 | 2022-03-24 | The University Of Manchester | Complementome assay |
-
2022
- 2022-03-16 GB GBGB2203627.1A patent/GB202203627D0/en not_active Ceased
-
2023
- 2023-03-16 WO PCT/EP2023/056794 patent/WO2023175099A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023175099A1 (en) | 2023-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289173A (en) | Compositions and methods for treating cns disorders | |
| IL294594A (en) | Methods for treating pemphigus disorders | |
| IL289172A (en) | Compositions and methods for treating cns disorders | |
| IL296215B1 (en) | Purine compounds for treating disorders | |
| IL310975A (en) | Lou064 for treating multiple sclerosis | |
| IL307607A (en) | Tetracyclic compounds for treating brain disorders | |
| IL292186A (en) | Compositions and methods for treating blood disorders | |
| GB202203627D0 (en) | Agents for treating complement-related disorders | |
| GB202314527D0 (en) | New treatment for pain | |
| IL317947A (en) | Methods for treating complement-mediated diseases | |
| IL288234A (en) | Compounds for the treatment of neuromuscular disorders | |
| CA3244720A1 (en) | Agents for treating disorders involving ryanodine receptors | |
| IL290319A (en) | Compound for combination treatment | |
| IL290770A (en) | Compounds and methods for treating oxalate-related diseases | |
| HUE064901T2 (en) | Treatment system for treating workpieces | |
| PL3733489T3 (en) | Treatment system for treating workpieces | |
| IL308424A (en) | Use of pelabresib for treating anemias | |
| IL291476A (en) | Pharmacological composition for treating proctological diseases (variants) | |
| GB202109675D0 (en) | Treatment for tyrosine degradation-associated disorders | |
| IL289018A (en) | Methods for treating neurodegenerative disorders | |
| GB202116350D0 (en) | Agents for treating senescence-associated diseases or disorders | |
| GB202002038D0 (en) | Compounds for treating bone disorders | |
| GB202007652D0 (en) | Compounds for treating covid-19 | |
| HK40100817A (en) | Agents for treating disorders involving ryanodine receptors | |
| GB202308670D0 (en) | New formulations for treating opioid use disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| COOA | Change in applicant's name or ownership of the application |
Owner name: COMPLEMENT THERAPEUTICS LIMITED Free format text: FORMER OWNER: THE UNIVERSITY OF MANCHESTER, |
|
| AT | Applications terminated before publication under section 16(1) |